Agios Pharmaceuticals
AGIO
31.79
+0.07
+0.22%
Agios Pharmaceuticals
US · AGIO
#2841 by market cap
Listed 1970
31.79
+0.07
+0.22%
Live - 5344 symbols - heartbeat 450s ago
· 2026-10-07 19:54
After-hours
31.79
0.00%
- Market cap
- 1.90B
- P/E (TTM)i
- -4.53
- P/Bi
- 1.85
- EPSi
- -7.12
- Div yieldi
- 0.00%
- 52W posi
- 40%
Reader sentiment
Are you bullish or bearish on AGIO?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 9.97, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +48.03% YoY
Margins
- Gross margin
- 88.26%
- Operating margin
- -873.87%
- Net margin
- -764.01%
Key ratios & quality
- Altman Z-Scorei
- 9.97
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 94.39M | -- | -- | 0 | 14.24M | 26.82M | 36.50M | 54.03M |
| Gross profit | 92.99M | -- | -- | 0 | 12.54M | 23.94M | 32.33M | 47.68M |
| Selling & admin expenses | 114.15M | 102.01M | 115.11M | 121.45M | 121.67M | 119.90M | 156.78M | 180.28M |
| Research & development | 341.32M | 214.26M | 220.81M | 256.97M | 279.91M | 295.53M | 301.29M | 339.54M |
| Operating profit | -362.48M | -316.27M | -335.92M | -378.42M | -389.05M | -391.49M | -425.74M | -472.13M |
| Pretax profit | -346.03M | -301.41M | -329.31M | -356.51M | -231.80M | -352.09M | 717.97M | -413.80M |
| Tax | -- | -- | -- | -- | 0 | 0 | 44.24M | -1.02M |
| Net profit | -346.03M | -411.47M | -327.37M | 1.60B | -231.80M | -352.09M | 673.73M | -412.78M |
| Basic EPS | -6 | -7 | -5 | 27 | -4 | -6 | 12 | -7 |
| Diluted EPS | -6.03 | -6.86 | -4.74 | 26.55 | -4.23 | -6.33 | 11.64 | -7.12 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 8.73M | 12.46M | 12.88M | 19.97M | 20.75M | 44.75M |
| Gross profit | 7.64M | 10.75M | 11.20M | 18.09M | 19.43M | 41.75M |
| Selling & admin expenses | 41.53M | 45.87M | 41.27M | 51.61M | 48.30M | 51.55M |
| Research & development | 72.74M | 91.94M | 86.80M | 88.06M | 81.15M | 100.75M |
| Operating profit | -106.63M | -127.06M | -116.87M | -121.58M | -110.03M | -110.55M |
| Pretax profit | -89.29M | -112.02M | -103.43M | -109.06M | -99.11M | -100.70M |
| Tax | -- | -- | 0 | -1.02M | -- | -- |
| Net profit | -89.29M | -112.02M | -103.43M | -108.04M | -99.11M | -100.70M |
| Basic EPS | -2 | -2 | -2 | -2 | -2 | -2 |
| Diluted EPS | -1.55 | -1.93 | -1.78 | -1.85 | -1.69 | -1.69 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 613.78M | 611.70M | 636.68M | 1.06B | 832.77M | 833.84M | 965.60M | 942.05M |
| Cash & ST investments | 585.30M | 564.88M | 572.93M | 1.02B | 783.12M | 776.93M | 893.71M | 854.43M |
| Inventory | 869.00K | 7.33M | -- | 0 | 8.49M | 19.08M | 27.62M | 32.92M |
| Total assets | 858.46M | 890.74M | 852.95M | 1.44B | 1.24B | 937.12M | 1.66B | 1.30B |
| Total current liabilities | 93.50M | 92.89M | 94.39M | 59.83M | 62.63M | 67.96M | 81.16M | 82.21M |
| Short-term debt | -- | 6.92M | 7.41M | 11.16M | 13.66M | 15.01M | 16.78M | 18.39M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 170,920,000.00 | 250,213,000.00 | 453,452,000.00 | 145,761,000.00 | 137,904,000.00 | 126,099,000.00 | 122,243,000.00 | 104,111,000.00 |
| Total equity | 687.54M | 640.53M | 399.50M | 1.29B | 1.10B | 811.02M | 1.54B | 1.19B |
| Retained earnings | -1.10B | -1.52B | -1.84B | -238.76M | -470.56M | -822.65M | -148.92M | -561.71M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 968.62M | 1.02B | 1.03B | 942.05M | 834.84M | 717.67M |
| Cash & ST investments | 893.38M | 938.94M | 952.86M | 854.43M | 113.60M | 617.58M |
| Inventory | 29.61M | 30.85M | 32.03M | 32.92M | 35.09M | 30.15M |
| Total assets | 1.56B | 1.47B | 1.39B | 1.30B | 1.18B | 1.11B |
| Total current liabilities | 52.37M | 70.41M | 74.76M | 82.21M | 58.85M | 70.22M |
| Short-term debt | 17.20M | 17.59M | 17.99M | 18.39M | -- | 19.23M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 88,990,000.00 | 101,682,000.00 | 101,375,000.00 | 104,111,000.00 | 75,875,000.00 | 82,403,000.00 |
| Total equity | 1.47B | 1.37B | 1.28B | 1.19B | 1.11B | 1.03B |
| Retained earnings | -238.21M | -350.23M | -453.67M | -561.71M | -802.49M | -761.52M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -304.42M | -370.62M | -290.76M | -407.32M | -309.48M | -296.06M | -389.84M | -372.98M |
| Depreciation & amortization | 7.17M | 8.09M | 9.79M | 9.24M | 8.56M | 6.62M | 5.65M | 5.18M |
| Free cash flow | -311.41M | -382.65M | -304.87M | -413.06M | -314.36M | -314.56M | -391.53M | -387.29M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 516.21M | 277.20M | 0 | -802.49M | -- | -- | -- | -- |
| Ending cash balance | 70.50M | 80.93M | 127.44M | 203.13M | 139.26M | 88.21M | 76.25M | 89.13M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -111.49M | -77.12M | -88.15M | -96.21M | -118.92M | -57.31M |
| Depreciation & amortization | 1.28M | 1.26M | 1.37M | 1.27M | 1.36M | 1.35M |
| Free cash flow | -112.26M | -88.00M | -89.71M | -97.33M | -119.69M | -83.52M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 78.96M | 80.87M | 92.71M | 89.13M | 113.60M | 99.65M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -65.10 | -61.97 | -62.95 | 189.74 | -19.38 | -36.83 | 57.29 | -30.20 |
| ROA %i | -46.99 | -47.05 | -37.55 | 140.11 | -17.32 | -32.36 | 51.82 | -27.89 |
| ROIC %i | -68.20 | -54.82 | -50.23 | 169.39 | -18.99 | -37.25 | 50.68 | -33.13 |
| 5-year avg ROE %i | -51.42 | -59.96 | -66.43 | -17.20 | -3.93 | 1.72 | 25.57 | 32.13 |
| EBIT margin %i | -384.03 | -361.57 | -152.33 | -- | -2,732.07 | -1,459.52 | -1,166.47 | -873.87 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.56 | 6.59 | 6.74 | 17.79 | 13.30 | 12.27 | 11.90 | 11.46 |
| Quick ratioi | 6.37 | 6.25 | 6.07 | 17.12 | 12.54 | 11.47 | 11.06 | 10.52 |
| Debt / assetsi | 0.00 | 12.76 | 12.33 | 6.75 | 6.92 | 7.68 | 3.43 | 3.10 |
| LT debt / equityi | -- | 16.67 | 24.48 | 6.65 | 6.54 | 7.03 | 2.61 | 1.83 |
| Interest coveragei | -- | -- | -17.36 | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 16.88 | -- | -- | -- | -- | -- | -- | 55.97 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -25.12 | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 60.26 | 64.05 | -27.57 | -30.20 | -21.69 | -34.34 |
| ROA %i | 55.38 | 57.93 | -25.26 | -27.89 | -30.84 | -31.89 |
| ROIC %i | 53.38 | 56.11 | -30.63 | -33.13 | -23.98 | -36.97 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -1,188.86 | -1,129.13 | -1,061.80 | -873.87 | -719.97 | -466.78 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 18.50 | 14.48 | 13.82 | 11.46 | 14.19 | 10.22 |
| Quick ratioi | 17.12 | 13.41 | 12.81 | 10.52 | 1.93 | 9.14 |
| Debt / assetsi | 3.40 | 3.31 | 3.21 | 3.10 | 3.02 | 2.81 |
| LT debt / equityi | 2.44 | 2.28 | 2.07 | 1.83 | 0.70 | 1.16 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Product revenue, net100.00%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.